MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145495 | Name: CMC-583

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CMC-583 is a selective inhibitor of the MET receptor.

Chemical Structure

CMC-583
CMC-583
CAS#1029714-88-2

Theoretical Analysis

MedKoo Cat#: 145495

Name: CMC-583

CAS#: 1029714-88-2

Chemical Formula: C22H14FN5O2

Exact Mass: 399.1100

Molecular Weight: 399.39

Elemental Analysis: C, 66.16; H, 3.53; F, 4.76; N, 17.54; O, 8.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CMC-583; CMC583; CMC 583;
IUPAC/Chemical Name
2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoic acid
InChi Key
DQQPUNCZEKUXNJ-UHFFFAOYSA-N
InChi Code
1S/C22H14FN5O2/c23-18-10-15(4-5-17(18)21(29)30)20-12-26-22-25-11-16(28(22)27-20)9-13-3-6-19-14(8-13)2-1-7-24-19/h1-8,10-12H,9H2,(H,29,30)
SMILES Code
OC(=O)C1=CC=C(C=C1F)C2=NN3C(CC4=CC=C5N=CC=CC5=C4)=CN=C3N=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 399.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Remon J, Hendriks LEL, Mountzios G, García-Campelo R, Saw SPL, Uprety D, Recondo G, Villacampa G, Reck M. MET alterations in NSCLC-Current Perspectives and Future Challenges. J Thorac Oncol. 2023 Apr;18(4):419-435. doi: 10.1016/j.jtho.2022.10.015. Epub 2022 Oct 29. PMID: 36441095. 2: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583. 3: Dong Y, Xu J, Sun B, Wang J, Wang Z. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. Mol Diagn Ther. 2022 Mar;26(2):203-227. doi: 10.1007/s40291-021-00568-w. Epub 2022 Mar 10. PMID: 35266116; PMCID: PMC8942886. 4: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Capmatinib. 2023 May 15. PMID: 37247365. 5: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Capmatinib. 2023 Sep 8. PMID: 37782740. 6: Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, Granata B, Lazzari C, Pretelli G, Pasello G, Santarpia M. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? Int J Mol Sci. 2023 Jun 14;24(12):10119. doi: 10.3390/ijms241210119. PMID: 37373267; PMCID: PMC10299133. 7: Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer (Auckl). 2021 May 20;12:35-50. doi: 10.2147/LCTT.S269307. PMID: 34295201; PMCID: PMC8290191. 8: Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, Cortot AB. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer. 2023 Sep;24(6):483-497. doi: 10.1016/j.cllc.2023.06.008. Epub 2023 Jun 18. PMID: 37451931. 9: Dhillon S. Capmatinib: First Approval. Drugs. 2020 Jul;80(11):1125-1131. doi: 10.1007/s40265-020-01347-3. PMID: 32557339. 10: Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 May;156(6):1849-1861.e13. doi: 10.1053/j.gastro.2019.01.252. Epub 2019 Jan 31. PMID: 30711629; PMCID: PMC6904924. 11: Park HS, Abd El-Aty AM, Jeong JH, Lee T, Jung TW. Capmatinib suppresses LPS- induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses. Biomed J. 2023 Apr;46(2):100534. doi: 10.1016/j.bj.2022.04.005. Epub 2022 Apr 26. PMID: 35483573; PMCID: PMC10267969. 12: Blagosklonny MV. My battle with cancer. Part 1. Oncoscience. 2024 Jan 3;11:1-14. doi: 10.18632/oncoscience.593. PMID: 38188499; PMCID: PMC10765422. 13: Capmatinib (Tabrecta) for NSCLC. Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-e66. doi: 10.58347/tml.2023.1674d. PMID: 37039616. 14: Alzofon N, Jimeno A. Capmatinib for non-small cell lung cancer. Drugs Today (Barc). 2021 Jan;57(1):17-25. doi: 10.1358/dot.2021.57.1.3239638. PMID: 33594387. 15: Zhang Y, Du Z, Zhang M. Biomarker development in MET-targeted therapy. Oncotarget. 2016 Jun 14;7(24):37370-37389. doi: 10.18632/oncotarget.8276. PMID: 27013592; PMCID: PMC5095083. 16: Gálffy G, Morócz É, Korompay R, Hécz R, Bujdosó R, Puskás R, Lovas T, Gáspár E, Yahya K, Király P, Lohinai Z. Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. PMID: 38605928; PMCID: PMC11006988. 17: Chagas GCL, Rangel AR, El Osta B. MET alterations in advanced non-small cell lung cancer. Curr Probl Cancer. 2024 Apr;49:101075. doi: 10.1016/j.currproblcancer.2024.101075. Epub 2024 Mar 13. PMID: 38480027. 18: Blagosklonny MV. From osimertinib to preemptive combinations. Oncotarget. 2024 Mar 15;15:232-237. doi: 10.18632/oncotarget.28569. PMID: 38497774; PMCID: PMC10946407. 19: Hsu R, Benjamin DJ, Nagasaka M. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. Cancers (Basel). 2023 Jul 10;15(14):3561. doi: 10.3390/cancers15143561. PMID: 37509224; PMCID: PMC10377299. 20: Fraser M, Seetharamu N, Diamond M, Lee CS. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives. Cancer Manag Res. 2023 Nov 3;15:1233-1243. doi: 10.2147/CMAR.S386799. PMID: 37941971; PMCID: PMC10629434.